Wu Wen-Yong, Li Jun, Wu Zheng-Sheng, Zhang Chang-LE, Meng Xiang-Ling, Lobie Peter E
School of Pharmacy, and.
Exp Ther Med. 2011 Jul;2(4):647-653. doi: 10.3892/etm.2011.254. Epub 2011 Apr 11.
Altered expression of phosphorylated signal transducer and activator of transcription 3 (pSTAT3) and suppressor of cytokine signaling 3 (SOCS3) has been implicated in various types of human cancers. However, the clinical role of pSTAT3 and SOCS3 in hepatocellular carcinoma (HCC) is not well established. Immunohistochemical analysis of pSTAT3, SOCS3, Ki67 and VEGF expression was performed on tissue microarrays from 138 HCC patients. The expression of STAT3 mRNA was further detected by in situ hybridization. The association of pSTAT3 and SOCS3 expression with clinicopathological factors and patient survival was analyzed. Altered expression of pSTAT3 and SOCS3 was observed in HCC specimens, compared to adjacent non-tumor tissue. Increased expression of pSTAT3 was correlated with large tumor size, higher clinical stage, Ki67 and VEGF expression, as well as poor patient survival. Decreased expression of SOCS3 was correlated with the expression of Ki67, VEGF and pSTAT3, and poor patient survival. Moreover, the expression of pSTAT3 was conversely correlated with SOCS3 expression in HCC. Our results indicate that deregulated expression of pSTAT3 and SOCS3 may play roles in the development and progression of HCC. PSTAT3 and SOCS3 should be further evaluated as potential novel biomarkers for HCC prognosis.
磷酸化信号转导和转录激活因子3（pSTAT3）及细胞因子信号转导抑制因子3（SOCS3）的表达改变与多种人类癌症有关。然而，pSTAT3和SOCS3在肝细胞癌（HCC）中的临床作用尚未明确。对138例HCC患者的组织芯片进行了pSTAT3、SOCS3、Ki67和VEGF表达的免疫组织化学分析。通过原位杂交进一步检测STAT3 mRNA的表达。分析了pSTAT3和SOCS3表达与临床病理因素及患者生存的相关性。与相邻的非肿瘤组织相比，在HCC标本中观察到pSTAT3和SOCS3表达改变。pSTAT3表达增加与肿瘤体积大、临床分期高、Ki67和VEGF表达以及患者生存不良相关。SOCS3表达降低与Ki67、VEGF和pSTAT3表达以及患者生存不良相关。此外，在HCC中pSTAT3的表达与SOCS3的表达呈负相关。我们的结果表明，pSTAT3和SOCS3的表达失调可能在HCC的发生和发展中起作用。pSTAT3和SOCS3应作为HCC预后潜在的新型生物标志物进一步评估。
